WO2008043601A3 - Transdermales therapeutisches system mit zweiphasigem freisetzungsprofil - Google Patents

Transdermales therapeutisches system mit zweiphasigem freisetzungsprofil Download PDF

Info

Publication number
WO2008043601A3
WO2008043601A3 PCT/EP2007/058867 EP2007058867W WO2008043601A3 WO 2008043601 A3 WO2008043601 A3 WO 2008043601A3 EP 2007058867 W EP2007058867 W EP 2007058867W WO 2008043601 A3 WO2008043601 A3 WO 2008043601A3
Authority
WO
WIPO (PCT)
Prior art keywords
ergolin
compound
phase
therapeutic system
transdermal therapeutic
Prior art date
Application number
PCT/EP2007/058867
Other languages
English (en)
French (fr)
Other versions
WO2008043601A2 (de
Inventor
Johannes Tack
Bjoern Schurad
Antje Mueller-Schubert
Reinhard Horowski
Original Assignee
Axxonis Pharma Ag
Johannes Tack
Bjoern Schurad
Antje Mueller-Schubert
Reinhard Horowski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axxonis Pharma Ag, Johannes Tack, Bjoern Schurad, Antje Mueller-Schubert, Reinhard Horowski filed Critical Axxonis Pharma Ag
Priority to US12/311,305 priority Critical patent/US20100143475A1/en
Priority to JP2009530821A priority patent/JP2010505786A/ja
Priority to EP07802907A priority patent/EP2079458A2/de
Priority to AU2007306582A priority patent/AU2007306582A1/en
Publication of WO2008043601A2 publication Critical patent/WO2008043601A2/de
Publication of WO2008043601A3 publication Critical patent/WO2008043601A3/de
Priority to ZA2009/01959A priority patent/ZA200901959B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Die vorliegende Erfindung betrifft ein transdermales therapeutisches System (TTS) bestehend aus einer undurchlässigen Deckschicht, einer eine Ergolinverbindung der Formel (I) oder deren physiologisch verträgliches Salz oder Derivat enthaltenden Matrix, wobei R1 ein H-Atom oder ein Halogenatom und R2 eine Alkylgruppe mit 1 bis 4 Kohlenstoffatomen und ----- eine Einfach- oder Doppelbindung bedeutet, und einer abziehbaren Schutzschicht, wobei die Ergolinverbindung oder deren physiologisch verträgliches Salz oder Derivat durch ein Antioxidans und ein basisches Polymer stabilisiert ist. Das TTS zeichnet sich dadurch aus, dass in der Matrix mindestens ein Kohlenwasserstoff mit 8 bis 18 Kohlenstoffatomen in gerader oder verzweigter Kette, welcher am Ende der Alkylkette eine funktionelle Gruppe trägt, und/oder Aloe Vera Öl enthalten sind, so dass in einer ersten Phase (0-5 Stunden nach Applikation) lediglich 0-20% der therapeutisch angestrebten steady state- Plasmakonzentration der Ergolinverbindung erzielt werden und dann erst in einer zweiten Phase (5-20 Stunden nach Applikation) die therapeutisch angestrebte steady state- Plasmakonzentration der Ergolinverbindung erreicht wird.
PCT/EP2007/058867 2006-10-06 2007-08-27 Transdermales therapeutisches system mit zweiphasigem freisetzungsprofil WO2008043601A2 (de)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US12/311,305 US20100143475A1 (en) 2006-10-06 2007-08-27 Transdermal therapeutic system with two-phase release profile
JP2009530821A JP2010505786A (ja) 2006-10-06 2007-08-27 ２相性放出プロフィールを有する経皮治療システム
EP07802907A EP2079458A2 (de) 2006-10-06 2007-08-27 Transdermales therapeutisches system mit zweiphasigem freisetzungsprofil
AU2007306582A AU2007306582A1 (en) 2006-10-06 2007-08-27 Transdermal therapeutic system with two-phase releasing profile
ZA2009/01959A ZA200901959B (en) 2006-10-06 2009-03-20 Transdermal therapeutic system with two-phase releasing profile

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006048130A DE102006048130A1 (de) 2006-10-06 2006-10-06 Transdermales therapeutisches System mit zweiphasigem Freisetzungsprofil
DE102006048130.5 2006-10-06

Publications (2)

Publication Number Publication Date
WO2008043601A2 WO2008043601A2 (de) 2008-04-17
WO2008043601A3 true WO2008043601A3 (de) 2008-06-12

Family

ID=38704689

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/058867 WO2008043601A2 (de) 2006-10-06 2007-08-27 Transdermales therapeutisches system mit zweiphasigem freisetzungsprofil

Country Status (7)

Country Link
US (1) US20100143475A1 (de)
EP (1) EP2079458A2 (de)
JP (1) JP2010505786A (de)
AU (1) AU2007306582A1 (de)
DE (1) DE102006048130A1 (de)
WO (1) WO2008043601A2 (de)
ZA (1) ZA200901959B (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023107931A1 (en) * 2021-12-06 2023-06-15 Terran Biosciences, Inc. Salt and solid forms of indole analogs and methods of use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001068138A2 (en) * 2000-03-10 2001-09-20 Epicept, Inc. Intradermal-penetration agents for topical local anesthetic administration
WO2002015890A1 (de) * 2000-08-24 2002-02-28 Neurobiotec Gmbh Transdermales therapeutisches system
WO2003074035A1 (de) * 2002-03-06 2003-09-12 Hexal Ag Transdermalsystem mit fentanyl
WO2005025546A1 (de) * 2003-09-03 2005-03-24 Neurobiotec Gmbh Ergolinhaltiges mittel zur transdermalen applikation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4116912A1 (de) * 1991-05-18 1992-11-26 Schering Ag Mittel zur transdermalen applikation enthaltend ergolin-derivate
US5229130A (en) * 1991-12-20 1993-07-20 Cygnus Therapeutics Systems Vegetable oil-based skin permeation enhancer compositions, and associated methods and systems
DE19911262C2 (de) * 1999-03-13 2003-04-10 Scs Skin Care Systems Gmbh Vorrichtung zur Abgabe kosmetischer Wirkstoffe
US20070243240A9 (en) * 2000-08-24 2007-10-18 Fred Windt-Hanke Transdermal therapeutic system
WO2004112723A2 (en) * 2003-06-20 2004-12-29 Ronald Aung-Din Tropical therapy for the treatment of migraines, muscle sprains, muscle spasm, spasticity and related conditions
DE102004009903A1 (de) * 2004-02-26 2005-09-22 Grünenthal GmbH Pflaster mit reduzierter Hautirritation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001068138A2 (en) * 2000-03-10 2001-09-20 Epicept, Inc. Intradermal-penetration agents for topical local anesthetic administration
WO2002015890A1 (de) * 2000-08-24 2002-02-28 Neurobiotec Gmbh Transdermales therapeutisches system
WO2003074035A1 (de) * 2002-03-06 2003-09-12 Hexal Ag Transdermalsystem mit fentanyl
WO2005025546A1 (de) * 2003-09-03 2005-03-24 Neurobiotec Gmbh Ergolinhaltiges mittel zur transdermalen applikation

Also Published As

Publication number Publication date
US20100143475A1 (en) 2010-06-10
AU2007306582A1 (en) 2008-04-17
ZA200901959B (en) 2010-02-24
WO2008043601A2 (de) 2008-04-17
DE102006048130A1 (de) 2008-04-10
JP2010505786A (ja) 2010-02-25
EP2079458A2 (de) 2009-07-22

Similar Documents

Publication Publication Date Title
HN2009000784A (es) Dihidropirazolonas sustituidas
BRPI0720993B8 (pt) usos de compostos análogos de ciclopamina
CO6290687A2 (es) Inhibidores de cinasa pim y metodos para su uso
WO2008108378A3 (en) Bicyclic oxomorpholine derivative
TW200633695A (en) Methods for purifying trans-(-)-Δ9-tetrahydrocannabinol and trans-(+)-Δ9-tetrahydrocannabinol
WO2010136474A3 (en) Substituted aminobutyric derivatives as neprilysin inhibitors
SV2008003037A (es) Derivados de amina
WO2009066152A3 (en) Haloallylamine inhibitors of ssao/vap-1 and uses therefor
TW200800951A (en) Substituted imidazole compounds as KSP inhibitors
UA94606C2 (ru) Производные тиоксантина, композиция, которая их содержит, и их применение в терапии
HK1128005A1 (en) Compositions comprising glyceryl salicylate compounds
BRPI0914384A2 (pt) método para produzir pelo menos um composto desejado, uso pelo menos um composto substituinte, método para produzir um composto derivado, composto n-alcóxi-hexanodiol, método de produção de um composto, uso do composto, composto que possui pelo menos 37% de origem biológica e composto derivado
CL2007002519A1 (es) Compuestos derivados de aminopiridina, inhibidores selectivo sobre aurora a; composicion farmaceutica que comprende a dichos compuestos; combinacion farmaceutica que comprende a dichos compuestos, utiles para inhibir el crecimiento de celulas tumoral
UA97821C2 (en) Cyclized derivatives as eg-5 inhibitors
TW200716184A (en) Inhibitor for parakeratosis, pore reducing agent or skin roughening preventing or ameliorating agent and composition for skin care preparation
ATE528306T1 (de) Benzoxazepin-verbindungen, ihre herstellung und verwendung
WO2008151460A3 (en) Cooling compounds
WO2007126900A3 (en) Antifungal agents
CO6400188A2 (es) Inhibidores de la fosfodiesterasa tipo iii (pdeiii) o agentes sensibilizantes al ca2+ para elt ratamiento de la cardiomiopatia hepertrófica
UA97256C2 (ru) Замещенные пиразолы и триазолы как ингибиторы кбв (кинезин-белок веретена)
WO2008001391A3 (en) Site-specific inhibitors of histone methyltransferase [hmtase] and process of preparation thereof
ATE548019T1 (de) Hautaufhellende mittel, zusammensetzungen und verfahren
WO2010100133A3 (fr) Derives indoliques pour le traitement de maladies neurodegeneratives
RU2012129932A (ru) Средство для предотвращения или ослабления пигментации
BRPI0519199A2 (pt) composiÇço de viscossuplemento e uso da mesma

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07802907

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2007306582

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2009530821

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2007306582

Country of ref document: AU

Date of ref document: 20070827

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2007802907

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12311305

Country of ref document: US